spec sheet8 rows
Alniditan is a serotonin 5-HT1B/5-HT1D receptor agonist that was investigated by Janssen as an abortive treatment for acute migraine attacks, administered subcutaneously or intranasally.
- Studied as an abortive treatment for acute migraine attacks
- Showed high complete-relief rates in subcutaneous dose-finding trials
- More selective for 5-HT1B/1D than some triptans, with no meaningful activity at 5-HT1F
Overview
A close cousin of the triptans in what it does, but chemically unrelated to them; it worked well in trials and simply lost out commercially.
Mechanism
Alniditan is a benzopyran derivative, structurally distinct from the indole-based triptans (like sumatriptan) and from ergot derivatives. It acts as a potent, selective at 5-HT1B and 5-HT1D receptors, with reported potency roughly ten times that of sumatriptan at 5-HT1B and about twice that at 5-HT1D. Activation of these receptors on cranial blood vessels and trigeminal nerve terminals is thought to constrict dilated cranial vasculature and dampen the release of pro-inflammatory neuropeptides implicated in migraine.
receptor fingerprint
5-HT1B receptorAgonist
5-HT1D receptorAgonist
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
In dose-finding and open-label trials, subcutaneous and intranasal alniditan were generally well tolerated, with efficacy comparable to or exceeding sumatriptan at higher doses; adverse effects reported were consistent with the triptan-like class (injection site or nasal irritation, transient chest or neck sensations). It was never marketed, so long-term real-world safety data does not exist.
Subjective profileweighing the evidence above
It worked, it was well tolerated, and it still never reached a pharmacy, which is a commercial story rather than a scientific one. With several triptans actually on the market, there is no reason to chase it; read it as a footnote in migraine pharmacology.
Resources
This entry is here for reference.
Research
- 1.Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Subcutaneous Alniditan Study Group.
- 2.Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines
- 3.Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
3 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is Alniditan used for?
It was developed and tested as an acute, abortive treatment for migraine attacks, similar in purpose to the triptans.
How does Alniditan work?
It activates 5-HT1B and 5-HT1D serotonin receptors, which constrict overly dilated cranial blood vessels and reduce the release of inflammatory signals from trigeminal nerves during a migraine attack.
Is Alniditan well-researched?
It has real published human clinical trial data for migraine, including dose-finding and intranasal studies, though it was ultimately never approved.
Is Alniditan the same as a triptan?
It works on the same receptors as triptans but has a different chemical backbone (a benzopyran rather than an indole), so it is a related but distinct class of migraine drug.
Limitations of the evidence
- Never reached the market, so no approved-product safety record exists
Notes and cautions
- Trial data reports mostly mild, transient injection or nasal-related effects
- As a 5-HT1B/1D agonist it carries the same theoretical vasoconstrictive cautions as the triptan class